arrow
A

Angelantonio Maglio

Department of Medicine
H指数:19
被引数:1,425

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mindfulness-Based Interventions for Chronic Pulmonary Diseases: A Systematic Review of Effects on Anxiety, Depression, Stress, Dyspnea, and Quality of Life

基于正念的慢性肺部疾病干预措施:对焦虑、抑郁、压力、呼吸困难和生活质量影响的系统综述

2026-03-030
OAAI
Sex-Based Comparison of Remission in Patients with Severe Type 2 Asthma Treated with Biologics: A Real-World Analysis from the "Southern Italy Network on Severe Asthma Therapy"

性别对接受生物制剂治疗的严重2型哮喘患者缓解情况的比较:来自“意大利南部严重哮喘治疗网络”的真实世界分析

2026-01-010
PRE
Real-World Efficacy of Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium on Diaphragmatic Workload Assessed by Ultrasound and Lung Function in Patients with Uncontrolled Asthma

倍氯米松二丙酸酯/富马酸福莫特罗/格隆溴铵对膈肌负荷的影响:基于超声评估和肺功能的真实世界疗效研究(在未控制哮喘患者中)

2025-10-010
OAAI
Effect of the Arg16Gly β2-Adrenergic Receptor Polymorphism on Long-Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype-Stratified, Multicenter Study

Arg16Gly β2-肾上腺素能受体多态性对重度嗜酸性粒细胞哮喘患者长期美泊利单抗应答及临床缓解的影响:一项按基因型分层、多中心研究

2025-09-230
OAAI
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study

美泊利单抗治疗重度嗜酸性粒细胞性哮喘的长期临床和持续缓解: remi-m研究

2024-12-015
OAAI
Arg16Gly 132-Adrenoreceptor Polymorphism in Severe EosinophilicAsthma: Implications for Mepolizumab Long-Term Effectiveness and Clinical Remission
2024-10-300
PRE
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab
2024-10-100
PRE
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis
2024-06-0711
OAAI
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
2023-10-270
PRE